hydrochlorothiazide; valsartan · Novartis · NDA 020818
Diovan Hct
Earliest generic entry, as listed · earliest of 5 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 204687, Sciegen Pharms · 020818-001Approved 23 Apr 2026Detected 25 Oct 2026Historical import
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020818 · 001 · RLD | tablet, oral | 12.5MG;80MG | open |
| 020818 · 002 · RLD | tablet, oral | 12.5MG;160MG | open |
| 020818 · 003 · RLD | tablet, oral | 25MG;160MG | open |
| 020818 · 004 · RLD | tablet, oral | 12.5MG;320MG | open |
| 020818 · 005 · RLD | tablet, oral | 25MG;320MG | open |